drugset / Trial / NCT05957471

Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors

NCT05957471

Phase 1 Unknown 27 enrolled Biocity Biopharmaceutics Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase I study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC3195 in Patients with Locally Advanced or Metastatic Solid Tumors.

Timeline

Start
2023-06-26
Primary completion
2025-06
Completion
2025-06

Drugs

EvaluationDrugModalityDoseRoute
Subject BC3195 Unknown Intravenous

Indications

No indication recorded.